StockData
Sangamo Therapeutics, Inc logo

Sangamo Therapeutics, Inc (SGMOQ) stock

SGMOQOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q1 FY2026, quarter ended Mar 31, 2026Last filing: 10-Q on May 14, 2026Score 4/30
$0.10−0.01 (-8.17%)

Close on Oct 19, 2026Market cap $39.43MP/E –Yield –

Sangamo Therapeutics cash

Cash and short-term investments held at the end of each period.

Sangamo Therapeutics's cash was $27.59M at Mar 31, 2026. For fiscal 2025 it was $20.95M, down 50.0% from the year before. Over ten years it grew -11.3% a year on average. The highest annual figure on record is $642.92M in fiscal 2020.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$20.95M-50.0%
FY2024Dec 31, 2024$41.92M-48.2%
FY2023Dec 31, 2023$81.00M-73.7%
FY2022Dec 31, 2022$307.50M-18.7%
FY2021Dec 31, 2021$378.05M-41.2%
FY2020Dec 31, 2020$642.92M+76.6%
FY2019Dec 31, 2019$363.97M-9.8%
FY2018Dec 31, 2018$403.63M+63.5%
FY2017Dec 31, 2017$246.81M+1018.8%
FY2016Dec 31, 2016$22.06M-68.2%
FY2015Dec 31, 2015$69.48M+1052.3%
FY2014Dec 31, 2014$6.03M-93.5%
FY2013Dec 31, 2013$92.81M+46.1%
FY2012Dec 31, 2012$63.55M-24.5%
FY2011Dec 31, 2011$84.13M+39.6%
FY2010Dec 31, 2010$60.29M+184.9%
FY2009Dec 31, 2009$21.16M+9.0%
FY2008Dec 31, 2008$19.41M–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q1 FY2026Mar 31, 2026$27.59M+9.6%
Q4 FY2025Dec 31, 2025$20.95M-50.0%
Q3 FY2025Sep 30, 2025$29.62M-24.5%
Q2 FY2025Jun 30, 2025$38.34M+38.0%
Q1 FY2025Mar 31, 2025$25.18M-53.7%
Q4 FY2024Dec 31, 2024$41.92M-48.2%
Q3 FY2024Sep 30, 2024$39.20M-70.3%
Q2 FY2024Jun 30, 2024$27.79M-84.7%
Q1 FY2024Mar 31, 2024$54.42M-77.4%
Q4 FY2023Dec 31, 2023$81.00M-73.7%
Q3 FY2023Sep 30, 2023$132.10M-57.9%
Q2 FY2023Jun 30, 2023$182.10M-42.3%
Q1 FY2023Mar 31, 2023$241.00M-24.2%
Q4 FY2022Dec 31, 2022$307.50M-18.7%
Q3 FY2022Sep 30, 2022$313.57M-25.9%
Q2 FY2022Jun 30, 2022$315.72M-40.4%
Q1 FY2022Mar 31, 2022$317.80M-45.9%
Q4 FY2021Dec 31, 2021$378.05M-41.2%
Q3 FY2021Sep 30, 2021$423.41M-34.7%
Q2 FY2021Jun 30, 2021$529.65M-20.3%
Q1 FY2021Mar 31, 2021$587.08M+63.9%
Q4 FY2020Dec 31, 2020$642.92M+76.6%
Q3 FY2020Sep 30, 2020$648.83M+82.8%
Q2 FY2020Jun 30, 2020$664.85M+50.7%
Q1 FY2020Mar 31, 2020$358.13M+2.0%
Q4 FY2019Dec 31, 2019$363.97M-9.8%
Q3 FY2019Sep 30, 2019$354.85M-22.6%
Q2 FY2019Jun 30, 2019$441.10M-18.2%
Q1 FY2019Mar 31, 2019$351.00M+1043.0%
Q4 FY2018Dec 31, 2018$403.63M+63.5%
Q3 FY2018Sep 30, 2018$458.57M+1434.0%
Q2 FY2018Jun 30, 2018$539.45M+672.4%
Q1 FY2018Mar 31, 2018$30.71M+66.1%
Q4 FY2017Dec 31, 2017$246.81M+1018.8%
Q3 FY2017Sep 30, 2017$29.89M+6.8%
Q2 FY2017Jun 30, 2017$69.84M+439.1%
Q1 FY2017Mar 31, 2017$18.49M–
Q4 FY2016Dec 31, 2016$22.06M–
Q3 FY2016Sep 30, 2016$27.99M–
Q2 FY2016Jun 30, 2016$12.96M–

More Sangamo Therapeutics figures

See a number that looks wrong?